Background: The arachidonic acid metabolite 12(S)-HETE is suspected to enhance metastatic spread by inducing cancer cell-and lymph endothelial cell (LEC) motility. However, the molecular mechanisms leading to 12(S)-HETE-triggered cell migration are still elusive.
12(S)-HETE was described as the endothelial retraction factor (Honn et al, 1994) , which is physiologically secreted by activated macrophages (Rabinovitch et al, 1981) and platelets (Hamberg and Samuelsson, 1974) , functioning as a key that unlocks the lymphatic vasculature. In detail, 12(S)-HETE causes the disintegration of the adjacent lymph vessels due to downregulation of VE-cadherin and migration of lymph endothelial cells (LECs) in the opposite direction of the 12(S)-HETE gradient, thereby opening a gate within the vascular wall termed 'circular chemorepellent-induced defect' (CCID). Secretion of 12(S)-HETE is a general mechanism facilitating the transmigration of colon and breast cancer cells (Uchide et al, 2007) through CCIDs. 12(S)-HETE production is also a prerequisite for the development of metastases within lymph nodes and subsequently in distant organs (Kerjaschki et al, 2011) . Interestingly, neutrophils, which also use 12(S)-HETE as a key to move through vascular barriers (Rigby et al, 2015) , infiltrate and accumulate in the pre-metastatic lung before breast cancer cells arrive (Wculek and Malanchi, 2015) . 12(S)-lipoxygenase expression and 12(S)-HETE treatment was shown to induce colon cancer cell migration and correlates with their malignancy (Klampfl et al, 2012) . 12(S)-HETE binds to the G-protein coupled receptor 12-HETER (former orphan receptor GPR31) in prostate carcinoma cells and triggers a pro-migratory/invasive cell response (Guo et al, 2011) . This tempted us to investigate, whether 12(S)-HETE-triggered CCID formation and migration of LECs is mediated by 12-HETER, and to elucidate the downstream signalling pathway.
MATERIALS AND METHODS
Antibodies and reagents. Polyclonal rabbit anti-myosin light chain 2 (MLC2) antibody, polyclonal rabbit anti-phospho-Ser19 MLC2 antibody and polyclonal rabbit anti-myosin phosphatase target subunit 1 (MYPT1) were from Cell Signaling (Danvers, MA, USA). Polyclonal rabbit anti-phospho-MYPT1 (Thr696) was from Upstate (Lake Placid, NY, USA). Monoclonal mouse anti-b-actin (clone AC-15) antibody was from Sigma (Munich, Germany) and polyclonal rabbit anti-GPR31 (12-HETER) antibody from Cayman Chemical (Ann Arbor, MI, USA). Polyclonal rabbit anti-mouse and polyclonal swine anti-rabbit antibodies were from Dako (Glostrup, Denmark). Alexa-Fluor 488 (green) goat-anti-rabbit labelled antibody was purchased from Molecular Probes, Invitrogen (Karlsruhe, Germany).
Y27623, rhosin, blebbistatin and JAK inhibitor (pyridine P6) were purchased from Calbiochem (Darmstadt, Germany) and 12(S)-HETE from Cayman Chemical.
Small interfering RNA-targeting human 12-HETER (GPR31; SMART pool 'ON-TARGET plus', catalogue no.: L-005564-00-0005), and siRNA-targeting human MLC2 (catalogue no.: L-011087-00-0005) were ordered from Dharmacon (Gene Expression and Gene Editing, GE Healthcare, Lafayette, CO, USA). Nontargeting control (n.t.Co) RNA (Silencer Select Negative Control No. 1 siRNA, catalogue no.: 4390843) was from Ambion (Life Technologies, Carlsbad, CA, USA). All siRNAs were resuspended in RNAse-free water to a 20 mM stock.
Cell culture. Human MDA-MB231 and MCF-7 breast cancer cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and grown in MEM medium supplemented with 10% foetal calf serum, 1% penicillin/streptomycin and 1% non-essential amino acids (Gibco, Invitrogen). Telomerase immortalised human LECs were grown in EGM2 MV (Clonetics CC-4147, Allendale, NJ, USA). The cells were kept at 37 1C in a humidified atmosphere containing 5% CO 2 . For CCID formation assays, LECs were stained with Cytotracker-Green purchased from Invitrogen.
Spheroid generation. MDA-MB231 cells (input of 6000 cells per spheroid) or MCF-7 cells (input of 3000 cells per spheroid) were transferred to 30 ml serum-free MEM medium containing 6 ml of a 1.6% methylcellulose solution (0.3% final concentration). One hundred fifty microlitres of this cell suspension was transferred to each well of a 96-well plate (Greiner Bio-one, Cellstar 650185, Kremsmünster, Austria) to allow spheroid formation within 72 h.
CCID assay. The areas that are formed in the LEC monolayer upon contact with tumour spheroids are measured and are therefore a quantitative assay for lymph endothelial barrier breaching Nguyen et al, 2015) . The confluent Cytotracker-stained LEC monolayers (LECs were seeded into 24-well plates; Costar 3524, Sigma-Aldrich, Munich, Germany) were pre-treated with indicated inhibitors for 30 min before tumour cell spheroids were placed on the top. After 4 h of incubation, the CCID areas in the LEC monolayers underneath the spheroids were photographed using an Axiovert (Zeiss, Jena, Germany) fluorescence microscope to visualise Cytotracker (green)-stained LECs underneath the spheroids. CCID areas were calculated with the Zen Little software 2012 (Zeiss, Jena, Germany). For each condition the CCID size of 24 or more spheroids (unless otherwise specified) was measured.
Confocal microscopy and immunofluorescence analysis. Lymph endothelial cells were seeded in 1 ml EGM 2 MV onto Lab-Tek II chambered coverslips (Nalgen Nunc International, Wiesbaden, Germany) and allowed to grow for 2 days followed by cocultivation with MDA-MB231 spheroids on LEC monolayers. After 4 h of incubation, cells were washed with ice-cold phosphate buffered saline (PBS) and fixed in 4% paraformaldehyde for 15 min at room temperature. Cells were immunostained with anti-phospho-Ser19-MLC2 antibody (dilution 1 : 50) and analysed by confocal microscopy. For this, cells were washed with PBS and permeabilised with 0.3% Triton X-100 in PBS for 30 min at room temperature, followed by washing with PBS and blocking with 5% goat serum in PBS for 1 h. Cells were further incubated with a fluorescence labelled second antibody diluted 1 : 500 for 1 h at room temperature in the dark and washed with PBS. Cells were counterstained with DAPI (dilution 1 : 500 000) at room temperature.
Fluorescence intensity was analysed with Image-J software (National Institutes of Health, Bethesda, MD, USA). The results were expressed as 'mean grey value', which were subtracted to background intensity and normalised to analysed area.
Transfection of LEC monolayer. Lymph endothelial cells were seeded in 24-well plate (1 ml per well) and grown in EGM2 medium. Transfections were performed at 70-80% confluence. In all 0.75 mg siRNA (3 ml from 20 mM stock) and 6 ml HiPerFect Transfection Reagent (Qiagen, Hilden, Germany, catalogue no.: 301705) were mixed in 100 ml serum-free medium and incubated for 30 min at room temperature to allow the formation of transfection complexes. The old medium was replaced by 500 ml fresh EGM2 medium and the transfection complexes were added drop-wise to the cells (to a final siRNA concentration of 100 nM) and incubated for 24 h at 371 C. Then, the medium was replaced by fresh medium and cells were incubated for another 24 h to recover. Transfected LECs were used for CCID assays or to isolate RNA or proteins.
SDS-polyacrylamide gel electrophoresis (PAGE), western blotting and densitometry. SDS-PAGE and western blotting using the indicated antibodies was performed at least in triplicate to facilitate statistical analysis such as described recently (Nguyen et al, 2015) . Equal sample loading was controlled by Ponceau-S staining and -actin immunoblotting. Relative protein expression levels (controls were set to 1) were determined and normalised to phospho-protein levels, then to respective total protein expression and finally to -actin expression by densitometry.
12(S)-HETE assay.
MDA-MB231 and MCF-7 cells were seeded in 6-well plates and grown in 2.5 ml complete MEM medium to B70-80% confluence. Cells were serum-starved for 24 h, and then cells were stimulated with 10 mM arachidonic acid for 4 h to facilitate 12(S)-HETE production. The concentration of 12(S)-HETE in the cellular supernatant was measured with minor modifications as described previously (Teichmann et al, 2014) using the 12(S)-HETE enzyme immunoassay kit (EIA, #ADI-900-050; Enzo Life Sciences, Lausen, Switzerland). Absorbance was measured with a Wallac 1420 Victor 2 multilabel plate reader (Perkin Elmer Life and Analytical Sciences, Shelton, CT, USA). The concentration of 12(S)-HETE in the cellular supernatant was normalised to cell number.
Statistical analysis. For statistical analyses Excel 2013 software and Prism 6 software package (GraphPad, San Diego, CA, USA) were used. The values were expressed as mean±s.e.m. and the Student's t-test was used to compare differences between controls and individual samples, whereas analyses of variance (one-way ANOVA) was used to analyse treatment groups. Statistical significance level was set to Po0.05.
RESULTS AND DISCUSSION
MLC2 is required for breast cancer spheroid-triggered LEC retraction. It was demonstrated that MCF-7 cells secrete 12(S)-HETE, which is packed into exosomes (Uchide et al, 2007) . Here, MDA-MB231 and MCF-7 breast cancer cells produced 12(S)-HETE accumulating in the cell culture medium to an average concentration of 111 ng ml À 1 (B347 nM) and 54 ng ml À 1 (B162 nM) per 1 Â 10 6 cells within 4 h, respectively. At the sites where breast cancer emboli intravasate into the lymphatic vasculature, tumour, cells have to directly contact the endothelial wall and thus the local concentration of 12(S)-HETE in the immediate proximity of adherent LECs must have been severalfold higher than 347 nM at least in the in vitro setting studied here.
12(S)-HETE at a concentration level of 0.5-1.5 mM induced Ser19-phosphorylation of MLC2, which is indicative for the activation of this migration marker ( Figure 1A) . Therefore, to study the mechanisms of LEC retraction and CCID formation, LECs were further on treated with 1 mM 12(S)-HETE. Activated MLC2 induces F-actin stress fibres and cell mobility (Sun et al, 2013; Murata et al, 2014) . Accordingly, knockdown of MLC2 in LECs by siRNA (siMLC2, Figure 1B ) attenuated LEC migration and CCID formation, which was triggered by triplenegative MDA-MB231 spheroids ( Figure 1C ). To test whether this is a general mechanism, hormone-dependent MCF-7 breast cancer cell spheroids were placed on top of LEC monolayers in which MLC2 expression was knocked down and also in the MCF-7/LEC co-culture model the formation of CCIDs was reduced ( Figure 1D) . Furthermore, the inhibition of MLC2 by 0.75 mM blebbistatin ( Figure 1E ) attenuated CCID formation significantly (B25%) and therefore, the data provide evidence that phosphorylation of MLC2 is involved in the signalling pathway that leads to LEC retraction and tumour intravasation in vitro. To avoid nonspecific adverse effects of pharmacological compounds or siRNA (or transfection reagent) their concentrations were kept as low as possible.
Immunofluorescence confirmed that not only isolated 12(S)-HETE but also MDA-MB231 spheroids induced MLC2 phosphorylation in LECs of the migratory-active rim zone of CCIDs ( Figure 1F and Supplementary figure S1 ) and in pulmonary artery endothelial cells as prerequisite for transcellular migration (Khuon et al, 2010) . Furthermore, it was shown that also MCF-7 spheroids activate MLC2 in LECs .
12-HETER mediates 12(S)-HETE signal transduction to MLC2.
Next, it was investigated whether 12-HETER expression was relevant for 12(S)-HETE-induced phosphorylation of MLC2 and for CCID formation. Therefore, LECs were transfected with siRNA against 12-HETER (si12-HETER), which significantly reduced the expression of 12-HETER protein (Figure 2A ). The treatment with 12(S)-HETE induced the phosphorylation of MLC2 in control LECs (transfected with n.t.Co). In contrast, in si12-HETERtransfected LECs 12(S)-HETE treatment failed to induce phosphorylation of MLC2 ( Figure 2B lanes 3 and 4) indicating that 12(S)-HETE induced the phosphorylation of MLC2 through 12-HETER. In addition, MDA-MB231 spheroid-induced CCID formation was significantly reduced (B30%) in si12-HETERtransfected LEC monolayers ( Figure 2C ). Therefore, 12-HETER contributes to 12(S)-HETE-induced MLC2 phosphorylation and CCID formation.
MLC2 phosphorylation and CCID formation is mediated via ROCK. Ser19 of MLC2 was shown to be phosphorylated by RHOassociated protein kinase (ROCK; Leung et al, 1996) . To elucidate the connecting signalling components between MLC2 activation and 12-HETER expression LECs were pre-treated with the ROCK inhibitor Y27623, which suppressed constitutive and 12(S)-HETEinduced phosphorylation of MLC2 ( Figure 3A) . Furthermore, MDA-MB231-induced CCID formation was dose-dependently inhibited by increasing concentrations of Y27623 ( Figure 3B ). ROCK phosphorylates Thr696 of myosin phosphatase targeting subunit 1 (MYPT1), which is a negative regulator of MLC2 (Aburima et al, 2013) . The phosphorylation of this amino acid is indicative for the inactivation of MYPT. Therefore, Thr696-MYPT phosphorylation results in a concomitant increase of Ser19-MLC2 phosphorylation (Xia et al, 2005) . 12(S)-HETE induced the phosphorylation of MYPT in LECs ( Figure 3A) , whereas the pre-treatment of LECs with Y27623 (inhibiting ROCK) suppressed 12(S)-HETE-induced MYPT1 phosphorylation ( Figure 3A lanes 3  and 4) . Thus, ROCK and MYPT contributed to 12(S)-HETEtriggered phosphorylation of MLC2 and lymph endothelial barrier breaching. Another pathway culminating in MLC2 activation and microvascular barrier hyper-permeability and dysfunction was reported through myosin light chain kinase particularly in response to inflammatory mediators (Rigor et al, 2013) .
MLC2 phosphorylation and CCID formation is mediated via RHO. RHO is the name given to the upstream activator of ROCK, which causes the unfolding of its kinase domain. To investigate whether RHO activity was required for 12(S)-HETE-induced MLC2 phosphorylation and for MDA-MB231-induced CCID formation, LECs were pre-treated with the specific RHO-GTPase inhibitor rhosin (Shang et al, 2012) . This prevented the induction of MLC2 phosphorylation in 12(S)-HETE-treated LECs ( Figure 4A ) and CCID formation by MDA-MB231 spheroids significantly ( Figure 4B ). G-protein coupled receptor GPR130 was shown to induce RHO, ROCK and migration through activation of JAK1 (Sanz-Moreno et al, 2011) . However, in MDA-MB231-induced CCID formation of LECs JAK1 was not involved, as demonstrated by the specific small molecule JAK inhibitor pyridone P6, which had no influence on this process ( Figure 4C ). Former studies demonstrated that the treatment of prostate carcinoma cells with 12(S)-HETE induced their invasivity, which depended on 12-HETER expression. This mechanism was sensitive to pertussis toxin indicating that the receptor signals through G aitype GTPases (Guo et al, 2011) . In contrast, G a12/13 -type GTPases and RHOA were shown to be responsible for the transduction of the 12(S)-HETE signal in mouse aortic endothelial cells (Bolick et al, 2005) . This suggests that 12(S)-HETE-triggered signal transduction may be mediated through distinct trimeric GTPases depending on the cell type. A schematic sketch depicts 12(S)-HETE-induced signalling cascades and effects in recipient cells ( Figure 5 ).
12(S)-HETE
Whereas RHOA negatively regulates endothelial barrier function, RAC1 and CDC42 stabilise vascular barriers (Spindler et al, 2010) . Currently, one clinical trial targeting the GTPases RAC and CDC42 with ketorolac (ovarian cancer; recruiting), and another trial targeting HMG-CoA (and also RAC and CDC42) with simvastatin in relapsed CCL (phase 1; completed, no data available), are the only cancer related studies, but there exist none that target RHO. There are two clinical trials targeting ROCK using AR-12286 and another two trials using fasudil (phase 2 and 3), but not in context with cancer treatment. Interestingly, one of the AR-12286 studies (phase 2, no data available) focusses on vascular function. No clinical trials target myosin, MYPT, MLC2 or 12-HETER (https://clinicaltrials.gov). The attempt to intervene on targets that reside high upstream of signalling cascades, such as RHO/RAC GTPAses, implicates that most of the downstream pathways that deviate from there are very likely affected as well. This may compromise the intended therapy due to severe side effects. Thus, hitting a downstream effector protein may provide a better concept largely avoiding undesired toxicity. Whether the unconventional intervention strategy to manipulate endothelial/ stromal response, as addressed in this in vitro investigation, supports conventional therapies at an early stage of disease is unpredictable and requires testing in vivo.
Conclusion. The present data propose that 12-HETER-RHO-ROCK-MYPT and MLC2 are involved in 12(S)-HETE-induced retraction of LECs and contribute to lymph endothelial disruption. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons AttributionNonCommercial-Share Alike 4.0 Unported License.
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